Maricann Secures Second-Site Sales License in Canada

Maricann (CSE:MARI) announced it was able to secure a second-site sales license for its location in Burlington, Ontario.
As quoted in the press release:

The sales licence is the second granted to Maricann by Health Canada, with the first applying to the company’s cultivation and processing facility in Langton, ON. With the granting of the new licence, Maricann is shifting its client services, sales operations and research activities to Burlington.
The establishment of the Burlington site helps Maricann centralize and streamline numerous sales and marketing processes, including potential same day delivery within the Greater Toronto Area, and next day delivery across Canada. Maricann is now moving through the process of establishing its analytical laboratory functions at the Burlington site, to assist in medical research efforts. This is expected to help scale the business at a faster rate.

Click here to read the full press release.

Source: www.marketwired.com